JPM vs MXCT · P/E 14, rev $57.35B vs rev $16.9M
JPMorgan Chase & Co (JPM) versus MaxCyte Inc (MXCT) — a side-by-side from cached financials, not a winner call.
JPMorgan Chase & Co (JPM) is a banks - diversified company listed on US. It is led by Jamie Dimon.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Latest reported JPM revenue for 2026-06-30 was $57.35B. Net income was $21.16B. Revenue was up 15.1% from 2026-03-31 to 2026-06-30. JPM currently screens at market cap $805.69B and trailing P/E 14.2.
Latest reported MXCT revenue for 2026-06-30 was $16.9M. Net income was -$13.6M. Revenue was up 75.3% from 2026-03-31 to 2026-06-30. MXCT currently screens at market cap $124.3M.
JPM currently screens at market cap $805.69B and trailing P/E 14.2. MXCT currently screens at market cap $124.3M.
Not investment advice. Open the JPM and MXCT stock pages for the full models.
Not investment advice.